Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. - Kolterman,OG.; Buse,JB.; Fineman,MS.; Gaines,E.; Heintz,S.; Bicsak,TA.; Taylor,K.; Kim,D.; Aisporna,M.; Wang,Y.; Baron,AD. (J Clin Endocrinol Metab, 2003)